Saturday, June 25, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Additional SARS-CoV-2 vaccine doses elicit robust seroresponse among patients receiving maintenance dialysis

by Medical Finance
in Coronavirus
Study: Seroresponse to third doses of SARS-CoV-2 vaccine among patients receiving maintenance dialysis. Image Credit: korokoso/Shutterstock
9
SHARES
102
VIEWS
Share on FacebookShare on Twitter

The decision to equip immunocompromised people with a third (booster) shot of an mRNA vaccine was taken by health authorities in mid-August 2021. However, it did not definitively include patients undergoing dialysis, with an increased risk for poor outcomes from coronavirus disease 2019 (COVID-19).


Study: Seroresponse to third doses of SARS-CoV-2 vaccine among patients receiving maintenance dialysis. Image Credit: korokoso/ShutterstockStudy: Seroresponse to third doses of SARS-CoV-2 vaccine among patients receiving maintenance dialysis. Image Credit: korokoso/Shutterstock


There has been increased morbidity and mortality from COVID-19 reported among patients undergoing maintenance dialysis, which is why there is a need to assess the impact of booster doses in this patient population.


Researchers thus recently published a report in the preprint server medRxiv* wherein they examined the seroresponse to an additional dose of vaccine in patients on maintenance dialysis.


Study details


Researchers examined the seroresponse to an additional dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine among patients at Dialysis Clinic, Inc. (DCI), catering for approximately 15,000 patients at 260 outpatient dialysis clinics in 29 states.


The study included all adult patients who received an additional SARS-CoV-2 vaccine dose after completion of the initial double-dose regimen and had at least one anti-spike IgG level checked both between the initial dosing and the additional dose and at least 14 days after the additional dose. The DCI electronic health record obtained demographic and clinical data, vaccination dates, history of COVID-19 diagnosis, and anti-spike IgG titer results.


Researchers assessed the patient population using hypothesized protective anti-spike protein IgG antibody threshold of 7 based on their previous work. For each patient, researchers identified three titer levels of interest:


  1. the maximum level of seroresponse reached at least 14 days after completion of the initial double-dose regimen but before the booster dose (labeled as “Max Pre”);
  2. the last titer measured before the booster vaccine dose (labeled as “Last Pre”); and
  3. the first titer measured after the booster dose (labeled as “First Post”).


In all analyses, strata of ≥20, 7-<20, 1-<7, and <1 Index were used. The threshold of 20 reflected the semi-quantitative nature of the assay used; the threshold of 7 represented a hypothesized level of protection from severe disease. The threshold of 1 reflected the manufacturer-recommended lower limit for defining seroresponse.


Among 395 patients receiving an mRNA vaccine regimen who were assessed, 384 (97%) had seroresponse ≥7 following the third booster dose. Among those with suboptimal (peak <7) and minimal (peak <1) seroresponse to an initial mRNA vaccine regimen, the rate of seroresponse ≥7 following a third dose was 97% (36 of 37) and 64% (14 of 22), respectively.


Given ongoing high rates of COVID-19 and rapidly waning immunity after an initial vaccine series, we recommend a third mRNA vaccine dose be standard for all patients receiving maintenance dialysis.


Implication


The study was crucial in determining the role of booster shots in maintenance dialysis patients, including a much-needed population of immunocompromised patients to the dataset. A third dose of the mRNA SARS-CoV-2 vaccine was associated with a high prevalence of seroresponse.


The booster dose successfully induced a robust seroresponse even among those with lapsed seroresponse. This highlighted the criticality of booster doses to maximize and sustain the protection of maintenance dialysis patients.


In the current scenario with the omicron-variant being highly transmissible, patients with increased risk like those on maintenance dialysis might as well be included in the booster-dose regimen.


*Important notice


medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: mRNA vaccine induces cytotoxic CD8+ T-cell cross-reactivity against SARS-CoV-2 Omicron variant and regulates COVID-19 severity. Image Credit: Design_Cells/ Shutterstock

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

by Medical Finance
June 25, 2022
0

In a recent study under consideration at Nature Portfolio Journal and posted to the Research Square* preprint server, researchers characterized...

Study: Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals, Image Credit: karegg / Shutterstock

Comparing SARS-CoV-2 Delta and Omicron waves in Germany

by Medical Finance
June 25, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers compared the outcomes and characteristics of hospitalized severe acute respiratory...

Study: Very Low Rates of Severe COVID-19 In Children Hospitalised with Confirmed SARS-Cov-2 Infection in London, England. Image Credit: Yuganov Konstantin / Shutterstock.com

Severe COVID-19 extremely rare among children

by Medical Finance
June 25, 2022
0

As of April 12, 2022, the coronavirus disease 2019 (COVID-19) pandemic has taken over 6.2 million lives, with over 500...

Study: COVID-19 Vaccination and Infertility Treatment Outcomes. Image Credit: Rido / Shutterstock.com

Does COVID-19 vaccination affect IVF treatments?

by Medical Finance
June 25, 2022
0

During the rollout of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), much controversy surrounded the alleged severe...

Study: SARS-CoV-2 and human retroelements: a case for molecular mimicry? Image Credit: Immersion Imagery / Shutterstock.com

Dysregulated retroelements associated with autoimmunity in COVID-19

by Medical Finance
June 25, 2022
0

The coronavirus disease 2019 (COVID-19) causes a wide variety of symptoms, with the vast majority of individuals suffering from a...

Study: Omicron BA.1 and BA.2 immune response in naïve and prior infected persons. Image Credit: Ninc Vienna / Shutterstock

Antibody response following Omicron BA.2 infection is lower than BA.1

by Medical Finance
June 25, 2022
0

In a recent report posted to the medRxiv* preprint server, researchers determined immune responses generated by the severe acute respiratory syndrome...

Next Post
Study: The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters. Image Credit: NIAID

Nitazoxanide shows promise for COVID-19 treatment in animal model

Study: Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice​​​​​​​. Image Credit: ktsdesign / Shutterstock

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • antibody in pink and red background selective focus 3d art Mirror Images A1 71b890c58eb74b42a6490cfe1b003dce 620x480
    Scientists reveal how COVID-19 impacts the immune system’s ability to recognize other coronaviruses
  • Study: Betacoronavirus-specific alternate splicing. Image Credit: Lightspring/Shutterstock
    Study demonstrates differential alternative splicing in betacoronaviruses
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply